Orthostatic hypotension – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 19 Jun 2026 04:02:37 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Orthostatic hypotension – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Ampreloxetine and Midodrine Hydrochloride for Treating Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy https://clinicaltrials.eu/trial/study-on-ampreloxetine-and-midodrine-hydrochloride-for-treating-neurogenic-orthostatic-hypotension-in-patients-with-multiple-system-atrophy/ Wed, 29 Apr 2026 14:23:36 +0000 https://clinicaltrials.eu/trial/study-on-ampreloxetine-and-midodrine-hydrochloride-for-treating-neurogenic-orthostatic-hypotension-in-patients-with-multiple-system-atrophy/ This clinical trial is focused on studying a condition known as Neurogenic Orthostatic Hypotension (nOH), which often affects people with Multiple System Atrophy (MSA). nOH is a condition where a person’s blood pressure drops significantly when they stand up, leading to dizziness or fainting. The study will evaluate the effectiveness and long-term benefits of a medication called Ampreloxetine, which is a selective norepinephrine reuptake inhibitor. This medication is being compared to a placebo to see how well it works in treating symptoms of nOH in people with MSA.

The trial will involve participants taking Ampreloxetine tablets over a period of time. Initially, there will be an open-label phase lasting 12 weeks, where all participants will receive the medication. This will be followed by a double-blind phase lasting 8 weeks, where participants will be randomly assigned to continue with either the medication or a placebo. The purpose of this study is to assess how well Ampreloxetine can improve symptoms and maintain its effects over time.

In addition to Ampreloxetine, the study will also involve the use of Gutron (midodrine hydrochloride), which is another medication used to treat low blood pressure. Participants will take these medications orally in tablet form. The study aims to provide valuable information on the potential benefits of these treatments for individuals with nOH and MSA, helping to improve their quality of life by managing symptoms more effectively.

]]> Study on the Effects of Fludrocortisone in Treating Neurogenic Orthostatic Hypotension in Patients https://clinicaltrials.eu/trial/study-on-the-effects-of-fludrocortisone-in-treating-neurogenic-orthostatic-hypotension-in-patients/ Wed, 29 Apr 2026 14:22:32 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-fludrocortisone-in-treating-neurogenic-orthostatic-hypotension-in-patients/ This clinical trial is focused on studying a condition known as neurogenic orthostatic hypotension. This condition occurs when a person’s blood pressure drops significantly upon standing, leading to symptoms like dizziness or fainting. The trial will evaluate the effectiveness and safety of a medication called fludrocortisone, which is marketed under the name Flucortac. Fludrocortisone is a type of medication that helps to increase blood pressure by retaining salt in the body, which can be beneficial for people with this condition.

The purpose of the study is to assess how well fludrocortisone works in managing the symptoms of neurogenic orthostatic hypotension over a period of four weeks. Participants will take the medication in tablet form, and their blood pressure will be monitored to see if there is an improvement when they move from lying down to standing up. Some participants may receive a placebo, which looks like the medication but does not contain the active ingredient.

Throughout the study, participants will be asked about their symptoms and overall quality of life to determine any changes. The study will also keep track of any side effects or unusual changes in blood pressure. This information will help researchers understand the potential benefits and risks of using fludrocortisone for treating neurogenic orthostatic hypotension.

]]>